Pharmaceuticals, Biotechnology and Life Sciences
Bristol-Myers Squibb said on Thursday that it won’t seek an accelerated approval for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.
Avacta expects to license Affimer technology in 2017, and it says this year is very optimistic for its shareholders.
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
French company Cerenis Therapeutics has seen some good things happen in the previous period in clinics by finalizing certain studies and getting FDA’s approval to kick some off. Also certain results showed progress and the company has reported solid cash position for the end of the year.
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…
According to preliminary consolidated results of Latvian JSC Olainfarm for December 2016, sales of the Groups have reached €10.28 million, which represents an increase by 39% compared to December 2015.
U.S. Food and Drug Administration (FDA) has approved Allergan’s Rhofade skin desease cream, a topical treatment of persistent facial erythema (redness)…
Anavex has ensured most of the cash for a U.S. multicentre Phase 2 clinical trial of Rett syndrome treatment Anavex2-73.
NeuroVive Pharmaceutical’s abstract with novel preclinical cancer data related to the company’s sanglifehrin-based compounds has been accepted for presentation at…
Summit Therapeutics has named its research and development adviser Dr David Roblin as new Chief Operating Officer (COO) and President of Research Development.